Pharma Mar SA (PHM) - Financial and Strategic SWOT Analysis Review
August 2019
50
About the Report
About the Report
Pharma Mar SA (PHM)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description-A detailed description of the company's operations and business divisions.
- Corporate strategy-Analyst's summarization of the company's business strategy.
- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history-Progression of key events associated with the company.
- Major products and services-A list of major products, services and brands of the company.
- Key competitors-A list of key competitors to the company.
- Key employees-A list of the key executives of the company.
- Executive biographies-A brief summary of the executives' employment history.
- Key operational heads-A list of personnel heading key departments/functions.
- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company's marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent indicated for the treatment of advanced or metastatic soft tissue sarcoma and relapsed ovarian cancer. Pharma Mar's developmental pipeline includes Aplidin (plitidepsin) for multiple myeloma and T-cell lymphoma; Zepsyre (lurbinectedin) for small cell lung cancer; and PM184 for advanced breast cancer and solid tumors. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, Belgium and the US. Pharma Mar is headquartered in Madrid, Spain.
Pharma Mar SA Key Recent Developments
Jul 29,2019: PharmaMar announces results for the first half of 2019
Jul 29,2019: Pharma Mar announces change in composition of-the board of directors
Apr 26,2019: PharmaMar Group reports results for the first quarter of 2019
Apr 09,2019: PharmaMar announces its new immunotherapy research program
Mar 26,2019: PharmaMar to attend the China Healthcare Investment Conference (CHIC)
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Products
Products
Pharma Mar SA, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts
Companies
Ability Pharmaceuticals SL
Ariad Pharmaceuticals (Spain) SL
GP Pharm SA
Traslational Cancer Drugs Pharma SL
CTI BioPharma Corp
Oryzon Genomics SA
Table of Contents
Table of Contents
Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1-About the Company
Pharma Mar SA-Key Facts
Pharma Mar SA-Key Employees
Pharma Mar SA-Key Employee Biographies
Pharma Mar SA-Major Products and Services
Pharma Mar SA-History
Pharma Mar SA-Company Statement
Pharma Mar SA-Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2-Company Analysis
Company Overview
Pharma Mar SA-Business Description
Business Segment: Biopharmaceuticals
Overview
Performance
Business Segment: Consumer Chemicals
Overview
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Italy
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Rest of the European Union
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: Spain
Performance
Geographical Segment: the US
Performance
R&D Overview
Pharma Mar SA-SWOT Analysis
SWOT Analysis-Overview
Pharma Mar SA-Strengths
Pharma Mar SA-Weaknesses
Pharma Mar SA-Opportunities
Pharma Mar SA-Threats
Pharma Mar SA-Key Competitors
Section 3-Company Financial Ratios
Financial Ratios-Capital Market Ratios
Financial Ratios-Annual Ratios
Performance Chart
Financial Performance
Financial Ratios-Interim Ratios
Financial Ratios-Ratio Charts
Section 4-Company's Lifesciences Financial Deals and Alliances
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Pharma Mar SA, Recent Deals Summary
Section 5-Company's Recent Developments
Jul 29, 2019: PharmaMar announces results for the first half of 2019
Jul 29, 2019: Pharma Mar announces change in composition of-the board of directors
Apr 26, 2019: PharmaMar Group reports results for the first quarter of 2019
Apr 09, 2019: PharmaMar announces its new immunotherapy research program
Mar 26, 2019: PharmaMar to attend the China Healthcare Investment Conference (CHIC)
Mar 21, 2019: PharmaMar: Soft Tissue Sarcoma requires a multidisciplinary approach to reduce patient relapses and improve patient survival
Feb 28, 2019: PharmaMar Group reports 2018 results
Oct 30, 2018: PharmaMar reports net profit of EUR5 million at the end of the third quarter of 2018
Oct 01, 2018: PharmaMar names Ali Zeaiter as new Director of Clinical Development
Aug 13, 2018: Immedica-a platform for pan-European niche specialty pharma launch, commercialization and distribution services
Section 6-Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Figure
List of Figures
Pharma Mar SA, Performance Chart (2014-2018)
Pharma Mar SA, Ratio Charts
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
List of Table
List of Tables
Pharma Mar SA, Key Facts
Pharma Mar SA, Key Employees
Pharma Mar SA, Key Employee Biographies
Pharma Mar SA, Major Products and Services
Pharma Mar SA, History
Pharma Mar SA, Subsidiaries
Pharma Mar SA, Key Competitors
Pharma Mar SA, Ratios based on current share price
Pharma Mar SA, Annual Ratios
Pharma Mar SA, Annual Ratios (Cont...1)
Pharma Mar SA, Annual Ratios (Cont...2)
Pharma Mar SA, Interim Ratios
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Pharma Mar SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.